Clinical Trial Update: Combination of Nivolumab and DHAP in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (Nivo-DHAP) [Phase 2]

View source ↗

Summary

A Phase 2 trial assessing the combination of nivolumab with DHAP in relapsed or refractory classical Hodgkin lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Classical Hodgkin Lymphoma
• Hodgkin Lymphoma

Drugs mentioned

• DHAP (dexamethasone, high-dose cytarabine, cisplatin)
• nivolumab (nivolumab)

Snippet

Sponsor: State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia | Conditions: Hodgkin Lymphoma | Phase 2 | Status: COMPLETED